# EDGAR Filing Document

**Accession Number:** 0000914475
**File Stem:** 0000914475-23-000023
**Filing Date:** 2023-3
**Character Count:** 4988
**Document Hash:** 36a6a8c216b1037c24996c8d59c9d727
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000914475-23-000023.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0000914475-23-000023

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230328

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230329

**DATE AS OF CHANGE**: 20230328

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEUROCRINE BIOSCIENCES INC
- **CENTRAL INDEX KEY:** 0000914475
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 330525145
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-22705
- **FILM NUMBER:** 23771479

**BUSINESS ADDRESS:**
- **STREET 1:** 12780 EL CAMINO REAL
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 617-7600

**MAIL ADDRESS:**
- **STREET 1:** 12780 EL CAMINO REAL
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

?xml version="1.0" ? nbix-20230328

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 28, 2023

![nbix-20230328_g1.jpg](nbix-20230328_g1.jpg)

**NEUROCRINE BIOSCIENCES, INC.**

(Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **0-22705** | **33-0525145** |
| (State or Other Jurisdiction | (Commission | (IRS Employer |
| of Incorporation) | File Number) | Identification No.) |
| **12780 El Camino Real,** | **12780 El Camino Real,** | |
| **San Diego,** | **California** | **92130** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) |

---

**(858) 617-7600**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value | NBIX | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 8.01. Other Events.**

On March 28, 2023, Neurocrine Biosciences, Inc. (the "Company") entered into an agreement with Teva Pharmaceuticals, Inc., and Teva Pharmaceuticals USA, Inc. (collectively, "Teva") resolving patent litigation related to INGREZZA<sup>®</sup>, the Company's medication for the treatment of tardive dyskinesia. The pending patent litigation was filed by the Company in the United States District Court for the District of Delaware in response to Teva notifying the Company that it had submitted an Abbreviated New Drug Application (ANDA) to the United States Food and Drug Administration seeking approval to market generic versions of INGREZZA prior to expiration of the Company's Orange Book listed patents. As a result of this settlement agreement, the Company has granted Teva the right to sell generic versions of INGREZZA in the United States beginning February 1, 2040 or earlier under certain circumstances. As required by law, the Company and Teva will submit the agreement to the United States Federal Trade Commission and the United States Department of Justice. Similar patent litigation brought by the Company against three other companies that filed ANDAs seeking approval to market generic INGREZZA remains pending with a trial date set for January 2, 2024.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| | **NEUROCRINE BIOSCIENCES, INC.** |
| Dated: March 28, 2023 | /s/ Darin M. Lippoldt |
| | Darin M. Lippoldt |
| | Chief Legal Officer |

---